Polysaturated fatty acids and their derivatives regulate respiratory infections.

The regulation of inflammation is a complex pathophysiological process that depends on the production of oxygenated lipid derivatives essential polyunsaturated fatty acids, like omega-3 and omega-6, among which are the lipoxins resolvins and protectins, called specialized pro-resolving lipid mediators (SPM). Their activity is associated with the control of respiratory infection processes to modulate the production of proinflammatory cytokines, avoiding damage due to inflammation-associated necrosis, reducing microbial loads, and promoting tissue remodeling. Therefore, we review some of the biochemical, physiological and immunological aspects of SPM in the regulation of inflammation in respiratory infections.Copyright © 2022, Instituto Nacional de Enfermedades Respiratorias. All rights reserved.

Effect of education on the precariousness of work in times of COVID-19 in Mexico

In this research, the relationship between the precariousness of working conditions and the education level of workers has been analyzed, for the months of the health crisis due to COVID-19 in Mexico. Through a sectorial analysis and using panel data in the months of April, May and June 2020 and in order to assess the occupational precariousness, an index was built and an economic model was estimated with the purpose of analyzing the interaction among the study variables. It was found that the health crisis due to COVID-19 increased the occupational precariousness. This cogency is the basis for the labor and educational policies. It is limited by the information which is still scarce and limited in time. The originality of this research is its sectorial approach and its main contribution is the cogency of a positive relationship among the sectors with higher precariousness and workers with lower educational credentials. © 2021 The Author(s).

Prediction of the Impact of the End of year Festivities on the Local Epidemiology of COVID-19 Using Agent-Based Simulation with Hidden Markov Models

Towards the end of 2020, as people changed their usual behavior due to end of year festivities, increasing the frequency of meetings and the number of people who attended them, the COVID-19 local epidemic’s dynamic changed. Since the beginnings of this pandemic, we have been developing, calibrating and validating a local agent-based model (AbcSim) that can predict intensive care unit and deaths’ evolution from data contained in the state electronic medical records and sociological, climatic, health and geographic information from public sources. In addition, daily symptomatic and asymptomatic cases and other epidemiological variables of interest disaggregated by age group can be forecast. Through a set of Hidden Markov Models, AbcSim reproduces the transmission of the virus associated with the movements and activities of people in this city, considering the behavioral changes typical of local holidays. The calibration and validation were performed based on official data from La Rioja city in Argentina. With the results obtained, it was possible to demonstrate the usefulness of these models to predict possible outbreaks, so that decision-makers can implement the necessary policies to avoid the collapse of the health system. © 2022, The Author(s).

INTRAMUSCULAR SOTROVIMAB IS NONINFERIOR to INTRAVENOUS SOTROVIMAB for COVID-19

Background: Sotrovimab is a pan-sarbecovirus neutralizing monoclonal antibody shown to be safe and effective for the treatment of early COVID-19 in high-risk patients and retains activity against variants of concern, including delta and omicron. To facilitate wider access to sotrovimab, it was formulated to allow for either intramuscular (IM) or intravenous (IV) administration. Methods: COMET-TAIL (NCT04913675) is a Phase III, randomized, multicenter, open-label, noninferiority (NI) study of IM vs IV sotrovimab for the treatment of mild/moderate COVID-19 in participants ≥12 years of age at high risk of disease progression. Participants were randomized to receive sotrovimab by single 500 mg IV infusion or IM injection (500 mg or 250 mg). The primary objective was to evaluate the efficacy of 500 mg IM vs 500 mg IV sotrovimab in preventing hospitalization for >24 hours for acute management of illness due to any cause or death. The 250 mg IM arm discontinued early due to a greater number of hospitalizations seen in that arm. A 3.5% NI margin on the risk difference scale was prespecified. Results: COMET-TAIL enrollment occurred from Jun-Aug 2021, coinciding with a surge in the SARS-CoV-2 delta variant in southern USA. The majority (∼85%) of participants were Hispanic or Latino and ∼25% were ≥65 years of age. In the 500 mg IM sotrovimab arm, 10/376 (2.7%) participants compared with 5/378 (1.3%) in the sotrovimab 500 mg IV arm met progression criteria for the primary endpoint (adjusted risk difference: 1.07% [95% CI:-1.25%, 3.39%]), meeting the NI margin of 3.5%. The overall rate of adverse events and injection/infusion-related reactions was low and similar between the 500 mg treatment arms. Most injection-site reactions were mild (grade 1), occurred shortly after dosing, and were limited in duration. Disease-related events (DREs) were balanced between the 500 mg IV and 500 mg IM arms. The most frequent DREs were COVID-19 pneumonia and pneumonia. There was a low percentage of participants (∼1%) with serious adverse events across all treatment arms, and none were considered related to treatment. Two participants (1 with BMI 69 mg/kg2 and an 82-year-old man) in the 500 mg IM arm died due to progression of COVID-19;no deaths occurred in the 500 mg IV arm. Conclusion: In the COMET-TAIL trial, sotrovimab given by 500 mg IM injection was found to be noninferior to IV infusion and was well tolerated. The option of IM administration will expand the potential for outpatient treatment with sotrovimab.

Temporary Basic Income in Times of Pandemic: Rationale, Costs and Poverty-Mitigation Potential

The pandemic has exposed the costs of job and income losses. Emergency cash transfers can mitigate the worst immediate effects on people who lack access to safety nets. This research note provides estimates for a potential Temporary Basic Income (TBI) for poor and near-poor people across 132 developing countries, as well as the minimum cost of income support sufficient to mitigate the pandemic-induced poverty increase. The total monthly cost of the TBI ranges 0.27-0.63% of developing countries' combined GDP, depending on the choice: (i) top-ups on each country's average incomes up to a vulnerability threshold;(ii) transfers based on each country's median standard of living;or (iii) uniform transfers. This note argues that some form of TBI is within reach and can inform a larger conversation about how to build comprehensive social protection systems that make the poor and near-poor more resilient to economic downturns in the future.

Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Background. COVID-19 disproportionately results in hospitalization and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody that binds a highly conserved epitope of the SARSCoV-2 receptor binding domain and has an Fc modification that increases half-life. Sotrovimab retains activity against UK, S. Africa, Brazil, India, New York and California variants in vitro. Objectives. To evaluate the efficacy and safety of treatment with sotrovimab in high-risk, non-hospitalized patients with mild/moderate COVID-19, as part of the COMET-ICE clinical trial. Methods. Multicenter, double-blind, phase 3 trial in non-hospitalized patients with symptomatic COVID-19 and ≥1 risk factor for disease progression were randomized 1:1 to an IV infusion of sotrovimab 500 mg or placebo. The primary efficacy endpoint was the proportion of patients with COVID-19 progression, defined as hospitalization > 24 hours or death, due to any cause, ≤29 days of randomization. Results. The study met the pre-defined primary efficacy endpoint in a preplanned interim analysis: the risk of COVID-19 progression was significantly reduced by 85% (97.24% CI, 44% to 96%;P = 0.002) in 583 patients. In the final intention-to-treat analysis (N = 1057), the adjusted relative risk reduction was 79% (95% CI, 50% to 91%;p< 0.001) through Day 29 in recipients of sotrovimab (n=528) vs. placebo (n=529). Treatment with sotrovimab (ITT) resulted in a numerical reduction in the need for ER visits for illness management, hospitalization for acute illness management (any duration) or death (any cause) compared to placebo. No participants on sotrovimab required ICU admission, compared to 9 participants on placebo, of whom 4 participants required mechanical ventilation. No participants who received sotrovimab died, compared to 4 participants on placebo. The incidence of adverse events was similar between treatment arms and SAEs were numerically more common in the placebo arm. Conclusion. Treatment with sotrovimab 500 mg IV resulted in a clinically and statistically significant reduction in progression of COVID-19 to hospitalization or death in patients with mild/moderate disease and was well-tolerated.

Measuring global poverty before and during the pandemic: a political economy of overoptimism

The contribution of this paper is to question the 'official' estimates of global monetary poverty up to and during the COVID-19 pandemic. We argue there is a political economy of overoptimism in the measurement of global poverty. Specifically, we show that the methodological and presentational choices can lead to an over optimistic view of the levels of, and trends in, global poverty. We provide an up-to-date critique of the global poverty estimates and demonstrate how patterns of poverty would differ if small changes in methodology were implemented. We conclude with a theoretical discussion of why such methodological choices that lead to an optimistic view of global poverty levels and trends are made. Subsequently, we propose an alternative approach to global poverty measurement.

Bioactive compounds from fungi with antiviral activities: Mechanism of action and biosynthetic pathways

Viral infections have affected human health, causing critical pandemics and mortality worldwide. Viruses can also cause enormous economic problems for society globally. Bioactive compounds isolated from fungi (both edible and nonedible) have shown potential activity against viruses. In this review, we describe the fungal natural compounds that have exhibited capability to inhibit some human pathogenic viruses, such as human immunodeficiency virus, dengue virus, herpes simplex virus, bovine herpes virus, influenza virus, respiratory syndrome virus, hepatitis virus among others. We focused on the biosynthetic pathways of fungal bioactive compounds and addressed the current knowledge about their antiviral mechanisms of action and specific targets. Fungal bioactive compounds are able to inhibit viral reproduction, blocking viral penetration, replication or translation as well as integrase or protease action. Fungal compounds able to inhibit protease such as. ganodermatriol, ergosterol, terpenoids, ganoderic acid GS-2, ganoderiol, sterigmatocystin, emericellin, cordycepin, ergosterol peroxide, myristic acid among others, may have a significant value to society at present, as they may have the potential to treat severe viral respiratory infections. Fungi represent a potential natural source of bioactive molecules that can be exploited for treating viral infections, which represent one of the main causes of disease worldwide. However, extensive investigations on clinical trials are required for the introduction of new antiviral agents into the market. © 2021 Verein zur Forderung des Open Access Publizierens in den Quantenwissenschaften. All rights reserved.